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Abstract
Introduction: Our goal was to examine the association between biological pathways and response to
chemotherapy in estrogen receptor (ER)-positive and ER-negative breast cancers separately.
Methods: Gene set enrichment analysis including 852 predefined gene sets, was applied to gene expression
data from 51 ER-negative and 82 ER-positive breast cancers that were all treated with a preoperative paclitaxel,
5-fluoruracil, doxorubicin and cyclophosphamide chemotherapy.
Results: Twenty-seven (53%) ER-negative and 7 (9%) ER-positive patients had pathologic complete response (pCR)
to therapy. Among the ER-negative cancers, a proliferation gene signature (FDR q = 0.1), the Genomic Grade Index
(FDR q = 0.044) and the E2F3 pathway (FDR q = 0.22, p = 0.07) signature were enriched in the pCR group. Among
the ER-positive cancers, the proliferation signature (FDR q = 0.001) and the Genomic Grade Index (FDR q = 0.015)
were also significantly enriched in cases with pCR. Ki67 expression, as single gene marker of proliferation, did not
provide the same information as the entire proliferation signature. An ER-associated gene set (FDR q = 0.03) and a
mutant p53-gene signature (FDR q = 0.0019) were enriched in ER-positive cancers with residual cancer.
Conclusion: Proliferation- and genomic grade-related gene signatures are associated with chemotherapy sensitivity
in both ER-negative and -positive breast cancers. Genes involved in the E2F3 pathway are associated with
chemotherapy sensitivity among ER-negative cancers. The mutant p53-signature and expression of ER-related
genes were associated with lower sensitivity to chemotherapy in ER-positive breast cancers only.
Introduction
Drug resistance is caused by multiple mechanisms that
operate simultaneously in cancers. A large number of
biological functions including transmembrane traffick-
ing, DNA-repair, stress response, proliferation and apop-
tosis may affect the sensitivity of a cell to chemotherapy.
Other, yet to be identified mechanisms may also play a
role. Preoperative chemotherapy provides an attractive
clinical setting to study mechanisms of drug resistance
in patients.
Chemotherapy before surgery is used in the treatment
of newly diagnosed, stage II-III breast cancers because it
frequently reduces tumor size and improves surgical
outcome [1]. Among patients who receive preoperative
chemotherapy, up to 25-30% (depending on the type of
treatment) experience complete eradication of the inva-
sive cancer in the breast and regional lymph nodes after
completion of 3-6 months of chemotherapy [2]. This
favorable response is called pathologic complete
response (pCR) and it indicates an extremely che-
motherapy sensitive tumor and also heralds excellent
long-term cancer-free survival [3]. We previously con-
ducted a pharmacogenomic study that included 133
patients with newly diagnosed breast cancer who
received preoperative chemotherapy with paclitaxel fol-
lowed by 5-fluorouracil, doxorubicin and cyclophospha-
mide. All patients underwent a one-time, pre-treatment
fine needle biopsy of the cancer for gene expression
analysis. The goal of the study was to discover gene-
expression based predictors of pCR. Our previous analy-
sis focused on discovering the best possible multi-gene
predictor without considering the function of any of the
genes [4]. The goal of the current analysis is to examine
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an association between known biological pathways and
response to chemotherapy.
Lists of genes (i.e. gene sets) that represent various
biological pathways were assembled from the literature.
We used gene set enrichment analysis (GSEA) to exam-
ine the correlation between these a priori defined gene
sets and chemotherapy response [5]. Clinical experience
as well as molecular analysis of breast cancers indicate
that estrogen receptor (ER)-positive and ER-negative
cancers are two different types of neoplastic diseases of
the breast therefore [6,7]. It is plausible that different
molecular mechanisms may determine response or resis-
tance to chemotherapy in these 2 types of breast can-
cers. Therefore, we performed our analysis separately
for ER-positive and ER-negative cancers.
Materials and methods
Patients
This study included 51 ER-negative and 82 ER-positive
tumors from patients with newly diagnosed stage I-III
breast cancer. Each patient had a fine needle aspiration of
the cancer before starting chemotherapy. These needle
aspiration samples contain approximately 80% neoplastic
cells and few or no stromal cells or normal breast epithe-
lium [8]. All patients were treated with 6 months of preo-
perative chemotherapy with paclitaxel followed by 5-
fluorouracil, doxorubicin and cyclophosphamide. Patients
underwent surgery after completion of chemotherapy and
the resection specimens were examined by a pathologist
to measure residual cancer. For the purpose of our analy-
sis, tumor response was dichotomized as pCR, defined as
no residual invasive cancer in the breast and lymph nodes,
or residual disease (RD) that included patients with any
degree of invasive cancer that survived preoperative che-
motherapy. The reason for this dichotomization was
because pCR is a strong surrogate for long term cancer-
free survival and therefore a marker of long-term benefit
from therapy [2,3]. It remains unknown to what extent
patients who achieve less than pCR benefit from che-
motherapy in terms of improved survival. This categoriza-
tion of pathologic response allowed us to compare
biological pathways between cancers with extreme che-
motherapy sensitivity (pCR) and the rest (RD). There were
not enough cases with tumor progression during treat-
ment in our study to form a third group including extreme
chemotherapy resistant tumors.
ER-status was determined from routine pathological
assessment by immunohistochemistry. The cut-off for
ER-positivity was ≥10% positive tumor cells following
standard clinical practice. This study was approved by
the institutional review boards (IRB) of MDACC and all
patients signed an informed consent for voluntary parti-
cipation. Clinical characteristics of the patients are pre-
sented in Table 1.
Gene expression analysis
Gene expression profiling was performed by using
Affymetrix U133A Gene Chips following standard
operating procedures as described previously [4]. We
normalized the gene expression data using dChip V1.3
software [9] to a single reference array. The normal-
ized gene expression values were transformed to a
log10 scale for further analysis. The complete microar-
ray data is available at the M.D. Anderson Cancer
Center bioinformatics web site [10]. To identify differ-
entially expressed genes between cases with pCR and
RD we performed unequal variance t-test on each
probe set. Because of the multiple comparisons many
low p-values are expected by chance alone. Under the
null hypothesis that no genes provide useful informa-
tion, the distribution of p-values should be uniform. If,
on the other hand, some genes do provide useful infor-
mation about predicting response, we would expect an
overabundance of small p-values (above what chance
might produce). We can capture this situation by mod-
eling the distribution of the p-values as a beta-uniform
mixture (BUM). This analysis was used to estimate
false discovery rates (FDR) that accompany particular
p-values derived from t-test [11]. All analysis was per-
formed using the R package (version 2.3.1).














T0 0 1 (1%)
T1 8 (16%) 4 (5%)
T2 24 (47%) 46 (56%)
T3/4 19 (37%) 31 (38%)
Histological grade
Grade 1 0 2 (2%)
Grade 2 6 (12%) 45 (55%)
Grade 3 43 (84%) 31 (38%)
Unknown 2 (4%) 4 (5%)
Lymph node status
Positive 38 (75%) 55 (67%)
Negative 13 (25%) 27 (33%)
HER2 over-expressed or
amplified
Yes 18 (35%) 15 (18%)
No 32 (63%) 67 (82%)
Unknown 1 (2%) 0
Pathologic complete response
Yes 27 (53%) 7 (9%)
No 24 (47%) 75 (91%)
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Gene set enrichment analysis
Gene set enrichment analysis (GSEA) was applied to
assess the association between pCR, RD, and 852 dis-
tinct a priori defined gene sets. The goal of the GSEA is
to determine whether members of a particular gene set
(i.e. a list of 15-500 probe sets that correspond to genes
that define a biological pathway) tend to occur toward
the top or the bottom of a rank ordered gene list
including all gene expression measurements [5]. We
ranked all probe sets based on their correlation with
pCR. Three groups of gene sets were tested, the first
included 319 distinct gene sets corresponding to probes
associated with 295 different cryptogenic bands on 24
chromosomes, the second included 522 different gene
sets corresponding to genes involved in various meta-
bolic and signaling pathways. A detailed description of
these gene sets and how they were assembled was pre-
sented by Subramanian et al [5]. The third group con-
tained 11 gene sets of various oncogenic or drug
resistance related pathways. These included 5 distinct
oncogenic pathways that were defined as genes overex-
pressed in normal human mammary epithelial cells
transfected with Myc, Ras, E2F3, b-catenin and Src
oncogenes, respectively and were described by Bild et. al
[12]. One mutated p53-associated gene set that was
defined as genes overexpressed in human breast cancer
with known p53 mutation and was previously described
by Miller et al [13]. It has been suggested that this gene
expression signature can distinguish cancers with wild
type and mutant p53 and it may outperform direct p53
gene sequencing as a predictor of prognosis and thera-
peutic response. We also assessed one ER-associated
gene set that contained genes that were most highly co-
expressed with the ER gene in human breast cancer
microarray data developed by Symmans et al [14]. This
gene set did not include the ER gene itself. We also
examined the genomic grade index (GGI) that repre-
sents genes that are differentially expressed between low
grade and high grade human breast cancers and were
identified by Sotiriou et al [15]. One prognostic signa-
ture that was derived by comparing gene expression
profiles of tumors that recurred with those that did not
was also tested. This prognostic signature was first
reported by Wang et al [16]. A proliferation signature
set reported by Whitfield et al that includes genes
involved in cell proliferation was also examined [17].
Finally, we also assessed an ATP-binding cassette trans-
porter (ABC) gene set that included genes involved in
drug transport and was previously shown to predict che-
motherapy response in cell lines by Szakacs et al [18].
Gene annotations were based on UniGene Build 185
that was used to match the genes in each of the above
publication to probe sets on Affymetrix U133 A gene
Chips. The gene sets are listed in Table 2 and a
complete list of all probe sets that comprise each of
the 852 sets is provided in supplementary Table 1
(Additional file 1).
Gene set enrichment score was calculated as reported
previously [5]. This score is a measure of the degree to
which a gene set is overrepresented at the extremes of
the entire ranked gene list. Significance was assessed by
permuting class labels (i.e. response category) and calcu-
lating enrichment scores for the permuted data sets that
yielded a null distribution. Nominal p-value for a score
was derived from comparison with this null distribution.
In order to adjust for multiple hypothesis testing, the
false discovery rate (FDR) q-value was calculated for
each gene set. The q-value could be considered as an
FDR-adjusted p-value; however unlike p-values which
express the probability of a false-positive result for a sin-
gle test, the q-value gives an estimate of the proportion
of false positives for a set of results [19]. Gene sets with
FDR q-value ≤ 0.25 were considered to be of interest
which indicates that the result is likely to be valid 3 out
of 4 times and represents a previously proposed cut off
in the literature [5]. Gene set enrichment analysis was
performed using R package of GSEA (version 1.0) pro-
vided by the Broad Institute of Massachusetts Institute
of Technology (Cambridge, MA).
Table 2 Gene sets used in this analysis






(n = 319 sets)
15-500 (variable) Subramanian et al. [5]
Functional sets
(n = 522 sets)
15-500 (variable) Subramanian et al. [5]
Oncogenic Pathways
(5 sets)








242 (183) Sotiriou et al. [13]
76-gene prognostic
signature (1 set)
76 (76) Wang et al. [14]
Proliferation signature
(1 set)
74 (44) Whitfield et al. [15]
ABC transporter gene set
(1 set)
61 (47) Szakacs et al. [16]
Mutant-p53 signature
(1 set)
25 (21) Miller et al. [11]
ER-associated gene set
(1 set)
200 (187) Symmans et al. [12]
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Results
Differentially expressed genes
Twenty-seven out of 51 patients (53%) had pCR among
the ER-negative tumors and 7 out of 82 (9%) among the
ER-positive tumors. The much lower response rate in
ER-positive cancers is consistent with previous reports
in the clinical literature [1-4]. First, we examined if we
could identify differentially expressed genes between
cases with pCR and RD using unequal variance t-test.
We performed this analysis separately for ER-negative
and ER-positive cancers. Figure 1 shows results of the
BUM analysis of the p values from the t-test. In ER-
negative cancers, the FDR rate associated with the low-
est p value (p ≤ 0.00087) was 40%. In ER-positive can-
cers, the FDR was close to 100% for all observed p
values. The scarcity of low p-values in the ER-positive
group is due to the unbalanced sample size (i.e. few
informative cases, 7 pCR only) and suggests and under-
powered analysis that violates t-test assumptions.
These observations indicate that in these 2 data sets,
t-test cannot reliably identify differentially expressed
genes. However, these results do not necessarily indicate
that there are no real transcriptional differences between
cases with pCR compared to RD when ER-positive and
ER-negative cancers are analyzed separately. It is possi-
ble, that no individual gene meets the threshold for sta-
tistical significance after correcting for multiple
hypotheses testing because the transcriptional differ-
ences are modest relative to the technical noise and bio-
logical variability that is present in the data. Analysis at
the single gene level may also miss small but coordi-
nated expression differences in a larger number of genes
that could belong to important biological pathways. In
some situations, small coordinated change in the expres-
sion of many genes that belong to a particular metabolic
pathway can have robust functional consequences [20].
Such subtle gene expression differences would not be
identified easily by pair-wise comparisons using t-statis-
tics. Different analytical tools, including gene set enrich-
ment analysis (GSEA) were developed to test for
potentially relevant but small scale transcriptional differ-
ences in pre-defined sets of genes.
Gene set enrichment analysis to identify pathways
associated with complete response to preoperative
chemotherapy
We applied GSEA to the 51 ER-negative tumors. Only 3
gene sets out of the 853 were enriched with an FDR q ≤
0.25. These gene sets included; (i) the proliferation set
(FDR q = 0.1, p = 0.05) (Figure 2A and Supplementary
Figure 1A in Additional file 2); (ii) the genomic grade
index set (FDR q = 0.04, p = 0.08) (Figure 2B and Supple-
mentary Figure 1B in Additional file 2); and (iii) the E2F3
pathway gene set (FDR q = 0.2, p = 0.07) (Figure 2C and
Figure 1 Distribution of p values computed from unequal variance t-test in patients with ER-negative and ER-positive tumors,
respectively. A, Gene expressions were compared between ER-negative tumors that had pathologic complete response and those that had a
lesser response to preoperative chemotherapy. The resulting p-values for all comparisons were modeled as beta uniform mixture. The straight
line indicates the contribution of the uniform component, and the curved line is the fitted beta-distribution from the observed values. Deviation
above the straight line indicate p-values that may represent true discovery. B, Distribution of p values in patients with ER-positive tumors.
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Supplementary Figure 1C in Additional file 2). All of these
were enriched in the group with pathologic complete
response, while no gene set was enriched in the group
with residual cancer.
We performed the same analysis on the 82 ER-positive
cases. Two gene sets were enriched in the group with
pathologic complete response including the proliferation
set (FDR q = 0.001, p = 0.002) (Figure 3A and Supple-
mentary Figure 2A in Additional file 3) and the genomic
grade index set (FDR q = 0.015, p = 0.01) (Figure 3B
and Supplementary Figure 2B in Additional file 3). In
the group with residual cancer, 2 other gene sets
showed enrichment including the ER-associated gene
list (FDR q = 0.03, p = 0.04) (Figure 3C and Supplemen-
tary Figure 2C in Additional file 3) and the mutant p53
gene signature (FDR q = 0.0019, p = 0.07) (Figure 3D
and Supplementary Figure 2 D in Additional file 3). The
complete list of probes and genes included in the five
enriched gene sets is presented in supplementary Table
2 (Additional file 4).
These results indicate that higher expression of prolif-
eration-related genes characterized cancers with pCR
among both ER-negative and ER-positive cancers. There
are several single gene markers of proliferative activity;
the one that is most commonly used in the clinic is
Ki67 (which was also included in the proliferation gene
set). We therefore examined if measuring Ki67 (MIK67)
mRNA expression alone is sufficient to separate cases
with pCR from those with residual disease after che-
motherapy. Ki67 expression is measured by 2 distinct
Affymetrix probe sets “212021_s_at” and “212023_s_at”.
In ER-negative cancers, neither of these probe sets were
significantly differentially expressed according to
pathologic response to chemotherapy (unequal variance
t-test, p = 0.97 and 0.92, respectively). In ER-positive
cancers, one of the 2 probe sets ("212023_s_at”) showed
borderline significant over-expression in the pathologic
complete response group, p = 0.06.
Also, since the ER-associated gene set was enriched in
ER-positive breast cancers with residual disease after
chemotherapy, we examined if quantitative assessment
of the ER (ESR1) mRNA alone could provide the same
information [21]. There was no statistically significant
difference in ER mRNA expression levels (probe set
“205225_at”) between cases with complete response and
those with residual cancer after chemotherapy (unequal
variance t-test, p = 0.09) among the ER-positive tumors.
Discussion
In the present study, we examined if we could find
individual genes or gene sets that are significantly
associated with extreme chemotherapy sensitivity in
ER-positive and ER-negative breast cancers, respec-
tively. These two major types of breast cancers differ
in the expression of thousands of genes [6,7,22]. They
also have substantially different sensitivity to cytotoxic
treatment; ER-positive cancers are generally less sensi-
tive to chemotherapy than ER-negative tumors [2].
Therefore, when these cancers are analyzed together,
sensitivity markers tend to identify ER-negative tumors
and are often dominated by genes that reflect the ER-
status of the tumor [4]. In order to identify markers of
response that are independent of ER-status we ana-
lyzed these 2 groups of breast cancers separately. To
our surprise, the commonly used approach which per-
forms gene wise comparison between responders and
Figure 2 Gene set enrichment results for ER-negative breast cancers. Running enrichment scores (RES) and the location of each probe set
within the complete ranked ordered gene list for each gene set. The first dotted line indicates the position of the maximum RES, the second
dotted line indicates the zero position of the ranking metric score. A, proliferation set (probe set n = 74). B, genomic grade index (probe set
n = 242). C, E2F3 pathway (probe set n = 173) (pCR = pathologic complete response; RD = residual disease). Heat maps corresponding to these
plots are provided on supplementary figure 1 in Additional file 2.
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non-responders failed to identify any genes that could
be declared differentially expressed with statistical con-
fidence. The estimated false discovery rate was > 40%
among the top differentially expressed genes in ER-
negative cancers and the FDR was even higher among
ER-positive cancers. These findings are in contrast
with the results that can be obtained when the entire
patient cohort is analyzed together. When we searched
for differentially expressed genes including both ER-
negative and -positive cases, we could identify over
400 genes with an FDR ≤ 1% [4].
We next examined if coordinated but relatively small
scale differences in the expression of sets of genes that
belong to functional pathways are associated with
response. Such small scale differences at the individual
gene level may not be readily identified by t-statistics
but gene set enrichment analysis may be able to detect
these. Two gene sets emerged as strongly enriched in
cancers with pCR to chemotherapy in both ER-positive
and ER-negative cancers. These included 44 genes (cor-
responding to 74 probe sets) involved in cell prolifera-
tion and 183 genes (corresponding to 242 probe sets)
Figure 3 Gene set enrichment results for ER-positive breast cancers. Results are presented as in figure 2. A, proliferation set. B, genomic
grade index: C, ER-associated genes (probe set n = 201). D, mutant p53 gene signature (probe set n = 25). Heat maps corresponding to these
plots are provided on supplementary figure 2 in Additional file 3.
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that distinguish histologically high grade cancers from
low grade tumors. These observations are consistent
with the literature that suggests that highly proliferative
cancers are more sensitive to cytotoxic treatment in
general [23]. However, there is no consensus how to
best measure proliferative activity [24]. To underscore
the power of gene set analysis, we noted that the prolif-
eration signature as a whole was significantly overrepre-
sented in highly chemotherapy sensitive tumors.
However, a commonly used proliferation marker Ki67
that was included in the signature showed no significant
over-expression when tested alone. It is also well docu-
mented in the clinical literature that high histological
grade is associated with better response to preoperative
chemotherapy [25]. It was reassuring to observe that the
same association holds up for the genomic grade index
too.
We also made 3 novel observations. Our results indi-
cate that the expression of genes involved in the E2F3
pathway may be associated with high degree of che-
motherapy sensitivity in ER-negative cancers. Consid-
ering that the E2F3 family of transcription factors
plays a critical role in regulating cell cycle progression
this association is not surprising [26]. Nevertheless, no
previous reports linked E2F3 activity to chemotherapy
response. It is also intriguing that no association
between E2F3 pathway and pCR was seen in ER-posi-
tive cancers. We also observed higher expression of
mutant-p53 associated genes in relatively chemother-
apy resistant ER-positive breast cancers. A similar
association was not seen among ER-negative cancers,
which suggests that p53 dysregulation may have differ-
ent consequences on chemotherapy sensitivity depend-
ing on the hormone receptor status of the cancer. This
may partly explain the conflicting results about the
role of p53 mutation in chemotherapy response in the
literature. Some studies suggested that functional p53
defects predict for increased sensitivity to anthracycline
chemotherapy [27]. Others reported that p53 muta-
tions are associated with resistance to anthracyclines
[28,29]. It has also been shown that breast cancer cell
lines exhibit different transcriptional response to che-
motherapy in vitro depending on their hormone recep-
tor status and molecular class. For example, the
expression of p21, a p53-regulated protein, was highly
induced in ER-positive cells, but only weakly in ER-
negative breast cancer cell lines in response to anthra-
cycline exposure [30]. This suggests that p53-mediated
apoptosis may be more important in ER-positive (lumi-
nal) than in ER-negative (basal-like) cells. Future bio-
marker studies will need to consider the possibility
that the predictive value of a biomarker may depend
on the molecular subtype of the cancer [31].
We also observed that those ER-positive cancers that
had low expression of ER-associated genes were more
sensitive to chemotherapy. This was independent of the
actual level of ER expression and indicates that some
ER-positive breast cancers do not posses the full tran-
scriptional signature of ER-activity. These cancers
showed increased chemotherapy sensitivity.
Our study has limitations. All patients received combi-
nation chemotherapy that represents the current stan-
dard of care for this patient population. This makes our
observations more relevant for clinical practice but at
the same time limits our ability to decipher drug-specific
response pathways. This could have biased our results
towards detecting “generic” drug sensitivity pathways
such as proliferation. The gene sets that we tested were
assembled from the published literature and often con-
tain overlapping genes represented in multiple gene sets.
Our current knowledge of biology is incomplete and
does not allow defining precisely all the genes that con-
tribute to a given biological process or represent a
unique molecular pathway. This may explain why the
majority of the 852 gene sets that we examined includ-
ing numerous apoptosis and signaling pathways did not
show enrichment by chemotherapy response. It is also
important to consider that GSEA is a method to
demonstrate that the expression of a given gene set is
overrepresented in a the top or bottom of particular
gene lists ranked by correlation with clinical outcome.
However, this method cannot be used to predict
response in a new case. How to translate GSEA results
into a prospective, single sample response predictor
remains an unsolved bioinformatics challenge.
Conclusion
We found that it is difficult to identify individual genes
associated with chemotherapy response with statistical
confidence when ER-negative and -positive breast can-
cers are analyzed separately. In contrast, GSEA revealed
several biological pathways that were associated with
response. These included proliferation related genes and
the genomic grade index that were enriched in cancers
with high sensitivity to chemotherapy regardless of ER
status. Genes included in the E2F3 pathway were also
enriched in ER-negative and highly chemotherapy sensi-
tive cancers. On the other hand, a mutant p53 gene
expression signature and a set of highly ER-associated
genes were enriched in ER-positive and chemotherapy
resistant cancers. These results suggest that proliferative
activity confers increased sensitivity to chemotherapy in
breast cancer in general, whereas other biological path-
ways such p53 mutation, E2F3 activation may be more
selective and influence chemotherapy sensitivity only in
particular molecular subtypes of breast cancer.
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Additional material
Additional file 1: Supplementary Table 1 includes a complete list of
all probe sets that comprise each of the 852 gene sets.
Additional file 2: Supplementary Figure 1 presents the same plots as
Figure 1 for ER-negative cancers but also includes heat maps of the
proliferation set (FDR q = 0.1, p = 0.05) (Supplementary Figure 1A); the
genomic grade index set (FDR q = 0.04, p = 0.08) (Supplementary Figure
1B); and the E2F3 pathway gene set (FDR q = 0.2, p = 0.07)
(Supplementary Figure 1C). All of these were enriched in the group with
pathologic complete response, while no gene set was enriched in the
group with residual cancer.
Additional file 3: Supplementary Figure 2 presents the same plots as
Figure 3 for ER-positive cancers but also includes heat maps of the
proliferation set (FDR q = 0.001, p = 0.002) (Supplementary Figure 2A)
and the genomic grade index set (FDR q = 0.015, p = 0.01)
(Supplementary Figure 2B). In the group with residual cancer, 2 other
gene sets showed enrichment including the ER-associated gene list (FDR
q = 0.03, p = 0.04) Supplementary Figure 2C) and the mutant p53 gene
signature (FDR q = 0.0019, p = 0.07) (Supplementary Figure 2D).
Additional file 4: Supplementary Table 2 includes the complete list of
probes and genes included in the five enriched gene sets.
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